Searched for
GLAXOSMITH KLINE PHARMACEUTICALS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
GlaxoSmithKline Pharma Q1 results: Net profit declines 2.38% to Rs 111 crThe company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said...
Neutral on GlaxoSmithKline Pharmaceuticals, target Rs 2500: Motilal OswalNeutral on GlaxoSmithKline Pharmaceuticals Ltd. at a price target of Rs 2500.
GlaxoSmithKline Pharmaceuticals to sell Thane land for Rs 555 croreThe proposed sale is subject to receipt of all statutory and regulatory approvals from the concerned authorities and signing of the definit...
CCI approves Corona Remedies-GlaxoSmithKline dealDilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
- Sell GlaxoSmithKline Pharmaceuticals with a target of Rs 1670: Centrum
The brokerage said that with double-digit sales growth in three out of four quarters, it expects the company to perform well.
GSK Pharma completes deal with Novartis HealthcareDrug firm GlaxoSmithKline Pharmaceuticals has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis...
GSK halves seretide price to take on CiplaAsthma patients may breathe easier as GSK has halved the prices of its Seretide inhaler in India to match that of Cipla’s competing brand S...
GSK raises India unit stake to 75% via open offerWe are very pleased with the outcome of this transaction, which further increases our exposure to a strategically important market," GSK Ch...
Cabinet okays coal regulator, pay panel termsThe decisions were announced after a meeting of the cabinet and the Cabinet Committee on Economic Affairs, which approved the measures. The...
GSK gets FIPB nod to buy 24.33% more in indian armThe Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33%stake, or 2.06 crore, equity shares in GlaxoSmithKline Pharmace...
Stockists, retailers have resumed product purchases: GlaxoSmithKline PharmaceuticalsGlaxoSmithKline Pharmaceuticals today said stockists and retailers have resumed purchasing its products across the country.
- Buy GlaxoSmithKline Pharmaceuticals with a target of 2350: Ashwani Gujral
GlaxoSmithKline Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 2350 and a stop loss of Rs 2200.
- GlaxoSmithKline net up 18 pc at Rs 136.74 crore
GlaxoSmithKline Pharmaceuticals said its net profit rose by 18.18 per cent to Rs 136.74 crore for the quarter ended December 31, 2011.
- GlaxoSmithKline 2010 net profit up 10.37 pc to Rs 560.57 cr
The company's board of director recommended a dividend of Rs 40 per share for the year ended December 31, 2010, in its meeting today.
- ViiV Healthcare seeks partners for HIV drug in India
Global drugmaker ViiV Healthcare is evaluating local partnerships to launch its patented HIV medicine maraviroc in India and is open to a d...